- Home
- NRIX
as 06-20-2025 4:00pm EST
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 952.9M | IPO Year: | 2020 |
| Target Price: | $30.44 | AVG Volume (30 days): | 796.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.18 - $29.56 | Next Earning Date: | 07-10-2025 |
| Revenue: | $56,417,000 | Revenue Growth: | -30.25% |
| Revenue Growth (this year): | 16.69% | Revenue Growth (next year): | -6.23% |
Stock Insider Trading Activity of Nurix Therapeutics Inc. Common stock (NRIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| van Houte Hans | NRIX | Chief Financial Officer | May 2 '25 | Sell | $11.33 | 6,198 | $70,242.55 | 33,724 | |
| van Houte Hans | NRIX | Chief Financial Officer | Apr 30 '25 | Sell | $11.50 | 2,438 | $28,041.14 | 33,724 | |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Apr 30 '25 | Sell | $11.50 | 3,377 | $38,841.24 | 61,516 | |
| Ring Christine | NRIX | Chief Legal Officer | Apr 30 '25 | Sell | $11.50 | 2,894 | $33,285.92 | 37,318 |
Latest Nurix Therapeutics Inc. Common stock News
NRIX Breaking Stock News: Dive into NRIX Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
8 days ago
RBC Raises Price Target on Nurix Therapeutics to $28 From $27, Keeps Outperform, Speculative Risk
GlobeNewswire
9 days ago
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
GlobeNewswire
15 days ago
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
Zacks
18 days ago
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?
MT Newswires
19 days ago
Sanofi Exercises Exclusive License for Nurix Therapeutics' STAT6 Program
Benzinga
19 days ago
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
GlobeNewswire
19 days ago
Sanofi Exercises License Extension Option to Nurix’s STAT6 Program
Compare NRIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.